Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous ...

In final draft guidance, NICE said an updated cost-effectiveness analysis had convinced it that Novartis' Afinitor (everolimus) daily pill in combination with exemestane (Pfizer's off-patent ...

Afinitor is another example of the value of ... Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. The FDA has also accelerated approval of Onyx ...

announced today that the Food and Drug Administration (FDA) has granted final approval of Everolimus Tablets for Oral Suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ ...

The approval is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) of strengths 2mg, 3mg and 5mg, Natco Pharma said in a regulatory filing. The drug is a ...

Hyderabad: NATCO Pharma Limited, an Indian pharmaceutical company, has announced the approval of its Abbreviated New Drug ...

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous sclerosis complex ("TSC") for the treatment of subependymal giant cell astrocytoma ...